Your browser doesn't support javascript.
loading
Multiple morbidities are associated with serious infections in patients with rheumatoid arthritis.
Kimbrough, Bradly A; Crowson, Cynthia S; Lennon, Ryan J; Davis, John M; Strangfeld, Anja; Myasoedova, Elena.
Afiliación
  • Kimbrough BA; Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
  • Crowson CS; Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; Department of Quantitative Health Sciences Division of Clinical Trials and Biostatistics, Mayo Clinic, 200 1st ST SW, Rochester, MN 55905, USA.
  • Lennon RJ; Department of Quantitative Health Sciences Division of Clinical Trials and Biostatistics, Mayo Clinic, 200 1st ST SW, Rochester, MN 55905, USA.
  • Davis JM; Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
  • Strangfeld A; Epidemiology and Health Services Research, German Rheumatism Research Centre (DRFZ) Berlin and Charite University Medicine, Charitéplatz 1, Berlin 10117, Federal Republic of Germany.
  • Myasoedova E; Division of Rheumatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address: Myasoedova.elena@mayo.edu.
Semin Arthritis Rheum ; 65: 152386, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38244447
ABSTRACT

OBJECTIVE:

To assess the association between a comprehensive list of morbidities and serious infection (SI) in patients with rheumatoid arthritis (RA).

METHODS:

This study evaluated SI risk associated with 55 comorbidities using a population-based inception cohort including all adult patients with incident RA from 1999 through 2014 with follow up through 2021. Morbidities and SI were ascertained using previously validated international classification of disease (ICD)-9 and ICD-10 codes. Conditional frailty models were utilized to analyze the association between each morbidity and SI Model 1 adjusted for age, sex, and calendar year; Model 2 adjusted for factors in Model 1 and the Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) Risk Score of Infections; and Model 3 adjusted for factors in Model 1 and the Mayo SI Risk Score.

RESULTS:

911 patients (70 % female, mean age 56 years, 66 % seropositive) were included. There were 293 SI among 155 patients (17 %), corresponding to an incidence of 3.9 SI per 100 person-years. Eighteen SI were fatal. Risk of SI was significantly increased in 27 of 55 morbidities in Model 1, 11 morbidities in Model 2, and 23 morbidities in Model 3. Additionally, several morbidities included in the RABBIT and Mayo risk scores continued to have large effect sizes despite adjustment. Serious infection risk increased by 11-16 % per morbidity in the three models.

CONCLUSIONS:

Several morbidities are associated with an increased risk for SI. Future risk scores may include morbidities identified in this study for improved SI risk assessment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Infecciones Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Semin Arthritis Rheum Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Infecciones Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Semin Arthritis Rheum Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
...